A COST-EFFECTIVENESS ANALYSIS OF POLATUZUMAB IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN PORTUGAL

被引：0
|
作者：
Pinheiro, B. [1 ]
Cardoso, M. [1 ]
Borges, M. [2 ]
Launonen, A. [3 ]
Ho, R. [3 ]
Miguel, Silva L. [1 ]
机构：
[1] Univ Lisbon, Ctr Estudos Med Baseada Evidencia, Fac Med, P-11 Lisbon, Portugal
[2] Univ Lisbon, Lab Farmacol Clin & Terapeut, Fac Med, Lisbon, Portugal
[3] F Hoffmann La Roche Ltd, Basel, Switzerland
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSA56
引用
收藏
页码：S43 / S44
页数：2
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS ANALYSIS OF POLATUZUMAB IN COMBINATION WITH RITUXIMAB AND BEVACIZUMAB FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
    Balmaceda, C.
    Abbott, T.
    Espinoza, M. A.
    VALUE IN HEALTH, 2020, 23 : S40 - S40
  • [2] US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma
    Betts, Keith A.
    Thuresson, Per-Olof
    Felizzi, Federico
    Du, Ella X.
    Dieye, Ibou
    Li, Jia
    Schulz, Mathias
    Masaquel, Anthony S.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2020, 9 (14) : 1003 - 1015
  • [3] COST-EFFECTIVENESS AND COST-UTILITY ANALYSES OF POLATUZUMAB VEDOTIN WITH BENDAMUSTINE AND RITUXIMAB VS. BENDAMUSTINE AND RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
    Bellone, M.
    Pradelli, L.
    Caputo, A.
    Ghislieri, D.
    Launonen, A.
    Ho, R.
    VALUE IN HEALTH, 2022, 25 (01) : S82 - S82
  • [4] Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma
    Patel, Kishan K.
    Isufi, Iris
    Kothari, Shalin
    Foss, Francine
    Huntington, Scott
    LEUKEMIA & LYMPHOMA, 2020, 61 (14) : 3387 - 3394
  • [5] Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab
    Amaya, M. L.
    Jimeno, A.
    Kamdar, M.
    DRUGS OF TODAY, 2020, 56 (04) : 287 - 294
  • [6] Bendamustine/rituximab in relapsed or refractory diffuse large B-cell lymphoma
    Vacirca, J. L.
    Acs, P. I.
    Shimkus, B. J.
    Rosen, P. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world
    Vodicka, Prokop
    Benesova, Katerina
    Janikova, Andrea
    Prochazka, Vit
    Belada, David
    Mocikova, Heidi
    Steinerova, Katerina
    Duras, Juraj
    Karban, Josef
    Hanackova, Veronika
    Sykorova, Alice
    Obr, Ales
    Trneny, Marek
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109 (02) : 162 - 165
  • [8] Cost-Effectiveness of Polatuzumab Vedotin Plus Bendamustine-Rituximab for Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the United States
    Betts, Keith A.
    Felizzi, Federico
    Dieye, Ibou
    Li, Jia
    Schulz, Mathias
    Hong, Samuel J.
    Masaquel, Anthony S.
    BLOOD, 2020, 136
  • [9] Polatuzumab Vedotin in Combination with Bendamustine Plus Rituximab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Our Experience
    Darcin, Tahir
    Yigenoglu, Tugce Nur
    Sahin, Derya
    Bakirtas, Mehmet
    Basci, Semih
    Merdin, Alparslan
    Yildiz, Jale
    Ulu, Bahar Uncu
    Tetik, Aysegul
    Iskender, Dicle
    Cakar, Merih Kizil
    Dal, Mehmet Sinan
    Altuntas, Fevzi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S249 - S250
  • [10] Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol
    Eslami, Mohammadreza
    Mehrabi, Mahdi
    Payandeh, Mehrdad
    Saba, Fakhredin
    PLOS ONE, 2024, 19 (08):
12345